Natco Pharma is moving beyond its traditional generics business as competition intensifies and growth in that sector slows, CEO Rajeev Nannapaneni said in an interview published on September 1. The company, known for producing complex generics, is exploring new avenues for expansion amid consolidation in the global generics market, according to livemint.com.
Nannapaneni explained that many Western pharmaceutical companies have exited the commodity generics space, leaving Indian drugmakers like Natco to compete fiercely among themselves. This shift has prompted Natco to reconsider its growth strategy, focusing on areas beyond generics to sustain earnings and market presence. The CEO emphasized the need to adapt as the generics market consolidates worldwide.
The global generics market has seen significant consolidation, with Western firms retreating and Indian companies facing heightened competition. Natco's pivot reflects broader industry trends where firms seek differentiation through innovation or niche products rather than competing solely on generic drug manufacturing. This approach aligns with moves by other Indian pharma companies aiming to diversify their portfolios and reduce dependency on crowded generics segments.
Natco Pharma’s strategic shift was detailed in an interview with CEO Rajeev Nannapaneni published by livemint.com on September 1, 2026, highlighting the company’s intent to explore growth beyond generics amid evolving market dynamics.